ADAR1 Capital’s Quiet Buying Surge Signals Bullish Bet on NextCure’s Pipeline—Stocks Rise 14% in a Week.
ADAR1 Capital’s cautious buying spree at $5 each signals bullish confidence in NextCure’s immunomedicine pipeline, potentially fueling a short‑term rally and boosting cash runway for future trials.
3 minutes to read